Exhibit 99.2

TO:          All Boston Scientific Employees
FROM:        Jim Tobin
             Pete Nicholas
SUBJECT:     Boston Scientific to Acquire Cardiac Pathways Corporation
DATE:        June 29, 2001

Today we are announcing that we have reached agreement to acquire Cardiac
Pathways Corporation, a publicly held company that designs, manufactures and
markets minimally invasive systems used by electrophysiologists to diagnose and
treat cardiac tachyarrythmias (abnormally rapid heart rhythms).

Cardiac Pathways Corporation's major technology platforms consist of systems for
ablating (destroying) the tissue in the heart that is responsible for starting
or maintaining the tachyarrythmia and systems for navigating EP catheters within
the heart. The attached press release contains specific details regarding
technologies, as well as some of the details of the agreement.

Cardiac Pathways' technologies complement our existing technologies in
electrophysiology (EP) - specifically our temperature-controlled ablation device
system - and further strengthen our product offerings in the EP catheter
ablation segment of the cardiac rhythm management market. The Chilli(R) Cooled
Ablation Catheter is the only fluid-cooled, EP catheter ablation technology
approved by the FDA, and the Realtime Position Management(R) (RPM) System is a
cardiac mapping and catheter navigation technology that helps physicians
identify and map the source of a tachyarrythmia and guide an EP catheter to the
target site.

We are establishing an integration team to evaluate and assess the full range of
potential opportunities resulting from the acquisition. In the weeks ahead, we
will be working to ensure that the integration is accomplished smoothly for both
our current and new employees.

The acquisition of Cardiac Pathways Corporation is subject to regulatory
approval and other customary conditions and should be finalized before the end
of the third quarter. Until the acquisition is complete, we will continue to
operate as separate and independent companies. In the time between now and the
final closing, no Boston Scientific salesperson, distributor, or any other
employee should make any representation or take any action with customers
regarding Cardiac Pathways' products and business.

We are very excited about this acquisition and the opportunity to strengthen our
EP franchise. We expect to augment our innovation, expand our product offering,
and grow our top line as a result of it.




As we move forward with the integration, we ask that you join us in welcoming
our new colleagues from Cardiac Pathways.

If you have any questions, please contact your manager or a Human Resources
representative.